JP3516526B2 - Stabilized enzyme-labeled antibody - Google Patents

Stabilized enzyme-labeled antibody

Info

Publication number
JP3516526B2
JP3516526B2 JP16535595A JP16535595A JP3516526B2 JP 3516526 B2 JP3516526 B2 JP 3516526B2 JP 16535595 A JP16535595 A JP 16535595A JP 16535595 A JP16535595 A JP 16535595A JP 3516526 B2 JP3516526 B2 JP 3516526B2
Authority
JP
Japan
Prior art keywords
antibody
enzyme
labeled
pod
solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP16535595A
Other languages
Japanese (ja)
Other versions
JPH0915241A (en
Inventor
正雄 中山
敏朗 朝比奈
Original Assignee
株式会社カイノス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社カイノス filed Critical 株式会社カイノス
Priority to JP16535595A priority Critical patent/JP3516526B2/en
Publication of JPH0915241A publication Critical patent/JPH0915241A/en
Application granted granted Critical
Publication of JP3516526B2 publication Critical patent/JP3516526B2/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Description

【発明の詳細な説明】Detailed Description of the Invention

【0001】[0001]

【産業上の利用分野】本発明は、経時安定性に優れた酵
素標識抗体、その調製方法、及び該酵素標識抗体を用い
た免疫学的測定方法に関する。
TECHNICAL FIELD The present invention relates to an enzyme-labeled antibody having excellent stability over time, a method for preparing the same , and an immunological assay method using the enzyme-labeled antibody .

【0002】[0002]

【従来の技術】免疫学的測定法に使用される酵素標識抗
体を調製するに際しては、抗体の標識方法について重要
なポイントが幾つかある。即ち、標識によって酵素や抗
体の活性が損なわれないこと、酵素と抗体の結合(架
橋)が安定していること、標識抗体としての経時安定性
に優れていること等である。
2. Description of the Related Art In preparing an enzyme-labeled antibody used in an immunological assay method, there are some important points regarding the antibody labeling method. That is, the label does not impair the activity of the enzyme or antibody, the bond (crosslinking) between the enzyme and the antibody is stable, and the labeled antibody is excellent in stability over time.

【0003】現在、酵素標識抗体を調製するには様々な
方法が知られているが、それらは大別すると三つに分類
することができる。すなわち、酵素と抗体を結合する
ために標識に用いる酵素に対する抗体を使用する方法、
酵素や抗体以外の蛋白分子を介して標識を行う方法、
そして架橋剤を用いて有機化学的結合により酵素と抗
体を結合する方法である。
At present, various methods are known for preparing enzyme-labeled antibodies, which can be roughly classified into three types. That is, a method of using an antibody against the enzyme used for labeling to bind the enzyme to the antibody,
A method of labeling via a protein molecule other than an enzyme or an antibody,
Then, it is a method of binding the enzyme and the antibody by an organic chemical bond using a crosslinking agent.

【0004】有機化学的結合による抗体の酵素標識法の
1つであるSIAB法は、架橋剤としてのN−スクシン
イミジル−(4−ヨードアセチル)−アミノベンゾエー
ト(以下SIABと略称する)あるいはSIABのスル
ホン化された化合物であるスルホスクシンイミジル−
(4−ヨードアセチル)−アミノベンゾエート(以下ス
ルホン化SIABと略称する)側のアミノ基と反応し得
る基(例えばN−スクシンイミド基)と抗体側のアミノ
基を反応させた後、β-ガラクトシダーゼの様なSH基
含有酵素或いはその他のSH導入酵素を架橋させること
により酵素標識抗体を得る方法である(例えば、Biotec
hniques 148,(1983)、特開昭55-34087号公報等
参照)。特開昭55-34087号公報には、上記方法
は標識効率が高く、得られた酵素標識抗体の非特異吸着
が少ないことが報告されている。
The SIAB method, which is one of the enzyme labeling methods for antibodies by organic chemical bonding, is N-succinimidyl- (4-iodoacetyl) -aminobenzoate (hereinafter abbreviated as SIAB) or a sulfone of SIAB as a crosslinking agent. Compound, sulfosuccinimidyl-
After reacting a group capable of reacting with an amino group on the side of (4-iodoacetyl) -aminobenzoate (hereinafter abbreviated as sulfonated SIAB) (for example, N-succinimide group) and an amino group on the side of an antibody, β-galactosidase It is a method of obtaining an enzyme-labeled antibody by crosslinking such SH group-containing enzyme or other SH introduction enzyme (for example, Biotec
hniques 148, (1983), JP-A-55-34087, etc.). JP-A-55-34087 reports that the above method has high labeling efficiency and little non-specific adsorption of the obtained enzyme-labeled antibody.

【0005】[0005]

【発明が解決しようとする課題】特開昭55−3408
7号公報に記載のような、抗体と架橋剤との結合を抗体
のアミノ基を利用して行い、また標識用酵素と架橋剤と
の結合を酵素のメルカプト基を利用して行う抗体の酵素
標識方法では、得られた酵素標識抗体の経時安定性が不
十分であるという欠点があり、そのため経時安定性の改
良された酵素標識抗体の出現が望まれていた。
Problems to be Solved by the Invention JP-A-55-3408
The enzyme of the antibody as described in JP-A-7-96, in which the antibody and the cross-linking agent are bound using the amino group of the antibody, and the labeling enzyme and the cross-linking agent are bound using the mercapto group of the enzyme. The labeling method has a drawback in that the stability of the obtained enzyme-labeled antibody over time is insufficient, and therefore, the appearance of an enzyme-labeled antibody with improved stability over time has been desired.

【0006】本発明の目的は、経時安定性に優れた酵素
標識抗体及びその調製方法を提供することにある。本発
明の他の目的は、この経時安定性に優れた酵素標識抗体
を用いた免疫学的測定方法を提供することにある。
An object of the present invention is to provide an enzyme-labeled antibody having excellent stability over time and a method for preparing the same. Another object of the present invention is to provide an immunological measurement method using this enzyme-labeled antibody having excellent stability over time.

【0007】[0007]

【課題を解決するための手段】本発明者らは上記問題を
解決すべく鋭意研究を行なった結果、特開昭55−34
087号公報にSIABのスクシンイミド基に標識酵素
のアミノ基を反応させてこれらを結合した場合には収率
の低下や特異性の欠如といった問題が生じることが記載
されているにも拘らず、標識酵素と抗体のSIABに結
合させる位置を従来の方法とは逆に入れ換えることで、
その経時安定性が格段に改善されることを見い出し、本
発明を完成した。
DISCLOSURE OF THE INVENTION The inventors of the present invention have conducted extensive studies to solve the above problems, and as a result, disclosed in JP-A-55-34
No. 087 describes that when a succinimide group of SIAB is reacted with an amino group of a labeling enzyme to bind them, problems such as a decrease in yield and lack of specificity occur, By replacing the positions of the enzyme and antibody that bind to SIAB in the opposite manner to the conventional method,
The inventors have found that the temporal stability is remarkably improved and completed the present invention.

【0008】本発明の酵素標識抗体は、抗体に標識酵素
を架橋剤を介して結合させた酵素標識抗体であって、下
記式(1):
The enzyme-labeled antibody of the present invention is an enzyme-labeled antibody obtained by binding a labeling enzyme to the antibody via a crosslinking agent, and has the following formula (1):

【0009】[0009]

【化3】 [上記式(1)中、Abは抗体を、PODはペルオキシ
ダーゼを表わす。]で表わされる構造を有することを特
徴とする。なお、上記式(1)において、−NH−はP
ODに由来し、−S−は抗体に由来する。
[Chemical 3] [In the above formula (1), Ab represents an antibody and POD represents a peroxidase. ] It has a structure represented by. In the formula (1), -NH- is P.
It is derived from OD and -S- is derived from antibody.

【0010】本発明において用いられる架橋剤は、SI
AB又はスルホン化SIABであり、これを用いてメル
カプト基を有する抗体とペルオキシダーゼを架橋結合さ
せることで本発明の酵素標識抗体を得ることができる。
The crosslinking agent used in the present invention is SI
It is AB or sulfonated SIAB, and the enzyme-labeled antibody of the present invention can be obtained by using this to cross-link the antibody having a mercapto group and peroxidase.

【0011】本発明の酵素標識抗体の調製に用いる抗体
としては、架橋剤としてのSIAB又はスルホン化SI
ABとの結合に利用するメルカプト(−SH)基を有す
るものが用いられる。抗体が−SH基を有するものでな
い場合は、これにメルカプト基を常法により導入して用
いれば良い。また、所望の抗原との反応性を有する抗体
のFab'フラグメントを調製してこれを用いても良い。
The antibody used for preparing the enzyme-labeled antibody of the present invention includes SIAB as a crosslinking agent or sulfonated SI.
Those having a mercapto (—SH) group used for binding to AB are used. When the antibody does not have a -SH group, a mercapto group may be introduced into this antibody by a conventional method before use. Alternatively, a Fab ′ fragment of an antibody having reactivity with a desired antigen may be prepared and used.

【0012】なお、抗体のFab'フラグメントとは、抗
体をペプシンによって分解した際に得られるF(ab')2
分のヒンジ部のジスルフィド結合を還元し、反応性のメ
ルカプト基を有するようにしたもので、抗体の抗原との
反応性を維持したものである。具体的な調製法として
は、後述の実施例における方法を挙げることができる。
The Fab 'fragment of an antibody means that the disulfide bond at the hinge portion of the F (ab') 2 fraction obtained when the antibody is digested with pepsin is reduced to have a reactive mercapto group. In this case, the reactivity of the antibody with the antigen is maintained. Specific methods for preparation include the methods described in the examples below.

【0013】本発明に用いる抗体としては、ポリクロー
ナル抗体或いはモノクローナル抗体のどちらでもよい。
抗体の具体例としては、抗AFP抗体、抗CA19-9
抗体、抗PSA抗体、抗CA-50抗体、抗TSH抗
体、抗FSH抗体、抗PRL抗体、抗LH抗体、抗ミオ
シン軽鎖抗体、抗ミオグロビン抗体、抗CK-MB抗
体、抗HCG抗体、抗インスリン抗体に少なくとも−S
H基を導入したもの、あるいはこれら抗体のF'abフラ
グメント等を挙げることができる。
The antibody used in the present invention may be either a polyclonal antibody or a monoclonal antibody.
Specific examples of the antibody include anti-AFP antibody and anti-CA19-9.
Antibody, anti-PSA antibody, anti-CA-50 antibody, anti-TSH antibody, anti-FSH antibody, anti-PRL antibody, anti-LH antibody, anti-myosin light chain antibody, anti-myoglobin antibody, anti-CK-MB antibody, anti-HCG antibody, anti-insulin At least -S for the antibody
Examples thereof include those into which an H group has been introduced, or F'ab fragments of these antibodies.

【0014】抗体と架橋剤との反応におけるこれらのモ
ル比は、所望の反応が得られるように設定すれば良く、
例えば、抗体1モルに対して架橋剤を2〜10モルの範
囲で用いることができる。
The molar ratio of these in the reaction between the antibody and the cross-linking agent may be set so that the desired reaction can be obtained.
For example, the crosslinking agent can be used in the range of 2 to 10 mol per mol of the antibody.

【0015】抗体と架橋剤との反応は、上記式(1)に
おける−S−CH2−からなる結合を得ることができる
条件で行われる。この反応は、例えば、適当な緩衝液等
の反応媒体中で、7.5〜8.5の範囲内のpH条件で
行うことができる。反応は、例えば4〜37℃の範囲温
度で行うことができる。
The reaction between the antibody and the cross-linking agent is carried out under the condition that a bond consisting of —S—CH 2 — in the above formula (1) can be obtained. This reaction can be carried out, for example, in a reaction medium such as a suitable buffer under pH conditions within the range of 7.5 to 8.5. The reaction can be carried out at a temperature in the range of 4-37 ° C, for example.

【0016】本発明において標識酵素として用いられる
ペルオキシダーゼ(以下、PODと略記する)は植物由
来のものであればよいが、なかでも西洋わさびPODが
好ましい。
The peroxidase (hereinafter abbreviated as POD) used as a labeling enzyme in the present invention may be plant-derived, but horseradish POD is particularly preferable.

【0017】本発明においてPODと架橋剤との反応モ
ル比はPODの1モルに対して架橋剤が10モル以上で
あれば良い。PODと架橋剤との反応は、以下に示すよ
うに、PODの有するアミノ基を利用して、PODと架
橋剤側の(スルホ)スクシンイミド基との置換反応によ
って上記式(1)中の−NH−を介した結合が得られる
ように行われる。
In the present invention, the reaction molar ratio between POD and the crosslinking agent may be 10 moles or more of the crosslinking agent to 1 mole of POD. As shown below, the reaction between POD and the cross-linking agent utilizes the amino group of POD, and the substitution reaction between POD and the (sulfo) succinimide group on the cross-linking agent side causes —NH in the above formula (1). It is done so that a coupling through the-is obtained.

【0018】[0018]

【化4】 (Rは水素原子または−SO3Naである。) この反応は、適当な緩衝液等の反応液媒体中で、7〜9
の範囲内のpHにおいて行うことができる。なお、pH
範囲の下限は7.5が、その上限は8.5がより好まし
い。反応は、例えば4〜37℃の範囲温度で行うことが
できる。
[Chemical 4] (R is a hydrogen atom or -SO 3 Na.) The reaction is carried out in the reaction liquid medium, such as suitable buffers, 7-9
Can be carried out at a pH within the range. In addition, pH
The lower limit of the range is more preferably 7.5, and the upper limit thereof is more preferably 8.5. The reaction can be carried out at a temperature in the range of 4-37 ° C, for example.

【0019】本発明における架橋剤としてのSIAB及
びスルホン化SIABの中では、スルホン化SIABは
SIABに比して水溶性が良好であるので、酵素標識抗
体の生成効率がより高いという利点がある。
Among SIAB and sulfonated SIAB as the cross-linking agent in the present invention, sulfonated SIAB has better water-solubility than SIAB, so that it has an advantage of higher production efficiency of enzyme-labeled antibody.

【0020】本発明の酵素標識抗体は、各種酵素免疫測
定法、発光免疫測定法等における抗体と結合し得る物質
の検出段階に好適に利用できる。
The enzyme-labeled antibody of the present invention can be suitably used in the step of detecting a substance capable of binding to the antibody in various enzyme immunoassays, luminescent immunoassays and the like.

【0021】例えば、間接法による場合、固相に固定し
た抗原に試料を反応させて、試料中に該抗原に対する標
的抗体が存在するかどうかを検定する場合、固定化した
抗原と試料との反応後に、これに本発明の酵素標識抗体
(抗体部分は標的抗体を抗原とする抗体からなる)を反
応させて、抗原−標的抗体−酵素標識抗体からなる複合
体を形成させて、この複合体を標識酵素を利用した呈色
反応で検出する。また、競合法や2抗体サンドイッチ法
などの他の手法においても、同様に酵素標識抗体の抗体
部分と結合する物質の検出段階に本発明の酵素標識抗体
が利用できる。
For example, in the case of the indirect method, when a sample is reacted with an antigen immobilized on a solid phase to test whether or not a target antibody against the antigen is present in the sample, the reaction between the immobilized antigen and the sample Thereafter, this is reacted with the enzyme-labeled antibody of the present invention (the antibody portion is composed of an antibody having a target antibody as an antigen) to form a complex composed of antigen-target antibody-enzyme-labeled antibody, and this complex is formed. It is detected by a color reaction using a labeling enzyme. Further, also in other methods such as the competitive method and the two-antibody sandwich method, the enzyme-labeled antibody of the present invention can be used in the step of detecting a substance that binds to the antibody portion of the enzyme-labeled antibody.

【0022】本発明の酵素標識抗体を用いて免疫学的測
定用キットを得ることができる。この免疫学的測定用キ
ットは、本発明の酵素標識抗体と、それを用いた免疫学
的測定方法に用いられる試薬及び/または器具を含むセ
ットである。例えば、上記の構成の酵素標識抗体溶液
と、 (1)標識酵素による発色反応を生じさせるために必要
な試薬類、 (2)検出対象としての抗原または抗体の標準溶液、 (3)検出対象としての抗原や抗体と、酵素標識抗体と
の反応に必要な試薬類や器具(例えば、反応用プレー
ト、試験管等)、 (4)検出対象としての抗原又は抗体を捕獲するための
固相に固定している抗体または抗原試薬の1種以上を組
合せてキットを形成することができる。
Immunological measurement using the enzyme-labeled antibody of the present invention
A regular kit can be obtained. This immunological measurement kit is a set containing the enzyme-labeled antibody of the present invention and reagents and / or instruments used in an immunological measurement method using the same. For example, the enzyme-labeled antibody solution having the above structure, (1) reagents necessary for causing a color reaction by the labeling enzyme, (2) a standard solution of an antigen or antibody as a detection target, (3) as a detection target Reagents and instruments (eg, reaction plates, test tubes, etc.) necessary for the reaction of the enzyme-labeled antibody with the above-mentioned antigen or antibody, (4) Immobilization on a solid phase for capturing the antigen or antibody to be detected Kits can be formed by combining one or more of the existing antibody or antigen reagents.

【0023】[0023]

【実施例】以下、実施例及び比較例により本発明をさら
に具体的に説明する。 実施例1 (スルホン化SIABを用いたPOD標識Fab'化マウ
ス抗TSHモノクローナル抗体の調製)IgクラスがI
gGに属するマウス抗TSHモノクローナル抗体(以
下、抗TSH抗体と略す)3mgを0.1Mクエン酸緩
衝液(pH4.5)1mlに加えて溶解した。これに1
%ペプシン溶液を0.35ml添加し、37℃、3.5
時間反応させた。反応物をゲル濾過カラムクロマトグラ
フィー(TSKgelG3000SW、東ソー(株)
製)で分離精製し、F(ab')2画分を回収した。得られた
F(ab')2画分に最終濃度が0.01Mになるように2−
メルカプトエチルアミンを添加した後、37℃で1.5
時間反応させた。反応後、反応物を脱塩処理して抗TS
H抗体Fab'フラグメントの溶液(溶媒:0.05Mリ
ン酸緩衝液:pH6.5、0.1M NaCl、2mM
EDTA)を得た。
EXAMPLES The present invention will be described in more detail below with reference to examples and comparative examples. Example 1 (Preparation of POD-labeled Fab'-modified mouse anti-TSH monoclonal antibody using sulfonated SIAB) Ig class is I
3 mg of a mouse anti-TSH monoclonal antibody (hereinafter abbreviated as anti-TSH antibody) belonging to gG was added to 1 ml of 0.1 M citrate buffer (pH 4.5) and dissolved. To this
% Pepsin solution (0.35 ml) was added, and the temperature was 37 ° C.
Reacted for hours. The reaction product was subjected to gel filtration column chromatography (TSKgel G3000SW, Tosoh Corporation).
(Manufactured by K.K.) and the F (ab ') 2 fraction was collected. The final concentration of the obtained F (ab ') 2 fraction was adjusted to 0.01M.
After adding mercaptoethylamine, 1.5 at 37 ° C
Reacted for hours. After reaction, the reaction product is desalted and anti-TS
Solution of H antibody Fab 'fragment (solvent: 0.05 M phosphate buffer: pH 6.5, 0.1 M NaCl, 2 mM
EDTA) was obtained.

【0024】次に、POD3mgに0.1Mリン酸緩衝
液(pH7.0)を0.3ml加えて溶解した。これに
2mg/mlの濃度にスルホン化SIABを含有する溶
液0.3ml添加した後、室温で1時間反応させた。反
応後、反応物の脱塩処理を行って、4−ヨードアセチル
−アミノベンゾエート・POD複合体の溶液(溶媒:
0.05Mリン酸緩衝液:pH6.5、0.1M Na
Cl、2mM EDTA)を得た。
Next, 0.3 ml of 0.1 M phosphate buffer (pH 7.0) was added to and dissolved in 3 mg of POD. To this was added 0.3 ml of a solution containing sulfonated SIAB at a concentration of 2 mg / ml, and the reaction was carried out at room temperature for 1 hour. After the reaction, the reaction product is desalted to give a solution of 4-iodoacetyl-aminobenzoate / POD complex (solvent:
0.05M phosphate buffer: pH 6.5, 0.1M Na
Cl, 2 mM EDTA) was obtained.

【0025】この4−ヨードアセチル−アミノベンゾエ
ート・POD複合体と、先の操作で得られたTSH抗体
Fab'フラグメントを0.1Mリン酸緩衝液(pH7.
5)中で直ちに混合し、4℃で16時間反応させた。反
応後、ゲル濾過カラムクロマトグラフィー(TSKge
lG3000SW)で分離精製を行い、POD標識Fa
b'化抗TSH抗体を調製した。
This 4-iodoacetyl-aminobenzoate / POD complex and the TSH antibody Fab 'fragment obtained in the previous operation were combined with 0.1 M phosphate buffer (pH 7.
5) was immediately mixed and reacted at 4 ° C. for 16 hours. After the reaction, gel filtration column chromatography (TSKge
1G3000SW) for separation and purification, and POD-labeled Fa
A b′-modified anti-TSH antibody was prepared.

【0026】比較例1 (スルホン化SIABを用いたPOD標識マウス抗TS
Hモノクローナル抗体の調製)比較のために、SIAB
を用いた酵素標識抗体の調製の従来法の例として、抗体
とスルホン化SIABとを、抗体のアミノ基を利用して
結合し、また、スルホン化SIABとPODを、POD
のメルカプト基を利用して結合することにより酵素標識
抗体を調製した。
Comparative Example 1 (POD-labeled mouse anti-TS using sulfonated SIAB
Preparation of H monoclonal antibody) For comparison, SIAB
As an example of a conventional method for preparing an enzyme-labeled antibody using, the antibody and the sulfonated SIAB are bound by utilizing the amino group of the antibody, and the sulfonated SIAB and POD are bound by POD.
An enzyme-labeled antibody was prepared by binding using the mercapto group.

【0027】即ち、抗TSH抗体3mgを0.1Mリン
酸緩衝液(pH7.0)0.3mlに加え溶解した。こ
れに2mg/mlの濃度のスルホン化SIAB溶液を
0.3ml添加し、室温で1時間反応させた後、反応物
を脱塩処理して4−ヨードアセチル−アミノベンゾエー
ト・抗TSH抗体複合体の溶液(溶媒:0.05Mリン
酸緩衝液:pH6.5、0.1M NaCl、2mM
EDTA)を得た。
That is, 3 mg of the anti-TSH antibody was added to 0.3 ml of 0.1 M phosphate buffer (pH 7.0) and dissolved. 0.3 ml of a sulfonated SIAB solution having a concentration of 2 mg / ml was added thereto, and the reaction was carried out at room temperature for 1 hour, and then the reaction product was desalted to prepare 4-iodoacetyl-aminobenzoate-anti-TSH antibody complex. Solution (solvent: 0.05 M phosphate buffer: pH 6.5, 0.1 M NaCl, 2 mM
EDTA) was obtained.

【0028】POD3mgに0.1Mリン酸緩衝液(p
H7.0)を0.3ml加え溶解した。これにS-アセ
チルメルカプトコハク酸無水物2mgをジメチルホルム
アミド50μlに溶解した液を加えた。この混合液を2
5℃、30分間インキュベーションした。次に500m
Mヒドロキシルアミンと10mM EDTAを含む10
0mM トリス−塩酸緩衝液0.2mlを加えてpH
7.0に調整した。この混合液を30℃、4分間静置し
た後、脱塩処理してメルカプト基を導入したPOD(S
H化POD)の溶液(溶媒:0.05Mリン酸緩衝液:
pH6.5、0.1M NaCl、2mM EDTA)
を得た。
POD (3 mg) was dissolved in 0.1 M phosphate buffer (p
0.3 ml of H7.0) was added and dissolved. To this was added a solution of 2 mg of S-acetylmercaptosuccinic anhydride dissolved in 50 μl of dimethylformamide. 2 this mixture
Incubated at 5 ° C for 30 minutes. Next 500m
10 containing M hydroxylamine and 10 mM EDTA
PH was adjusted by adding 0.2 ml of 0 mM Tris-HCl buffer.
Adjusted to 7.0. This mixed solution was allowed to stand at 30 ° C. for 4 minutes and then desalted to obtain a mercapto group-introduced POD (S
H-POD) solution (solvent: 0.05M phosphate buffer:
(pH 6.5, 0.1 M NaCl, 2 mM EDTA)
Got

【0029】このSH化PODと先の操作で得た4−ヨ
ードアセチル−アミノベンゾエート・抗TSH抗体複合
体を0.1Mリン酸緩衝液(pH7.5)中で直ちに混
合し、4℃で16時間反応させた後、ゲル濾過カラムク
ロマトグラフィーで分離精製を行い、POD標識抗TS
H抗体を調製した。
This SH-modified POD and the 4-iodoacetyl-aminobenzoate / anti-TSH antibody complex obtained by the above operation were immediately mixed in 0.1 M phosphate buffer (pH 7.5), and the mixture was mixed at 4 ° C. for 16 hours. After reacting for a period of time, separation and purification is performed by gel filtration column chromatography, and POD-labeled anti-TS
H antibody was prepared.

【0030】比較例2 (SMCCを用いたPOD標識抗体の調製)架橋剤をN
−スクシンイミジル−4−(N−マレイミドメチル)−
シクロヘキサン−1−カルボキシレート(SMCCと略
記する)とした場合の例として、POD標識Fab'化マ
ウス抗TSHモノクローナル抗体を調製した。
Comparative Example 2 (Preparation of POD labeled antibody using SMCC)
-Succinimidyl-4- (N-maleimidomethyl)-
As an example of the case of using cyclohexane-1-carboxylate (abbreviated as SMCC), POD-labeled Fab′-conjugated mouse anti-TSH monoclonal antibody was prepared.

【0031】即ち、まず、実施例1と同様にFab'化抗
TSH抗体の溶液を調製した。
That is, first, in the same manner as in Example 1, a Fab'-ized anti-TSH antibody solution was prepared.

【0032】次に、POD3mgに0.1Mリン酸緩衝
液(pH7.0)を0.3ml加え溶解した。これに1
00mg/ml SMCC・ジメチルホルムアミド溶液
を0.03ml添加し、室温で1時間反応させた後、反
応物を脱塩してマレイミド基導入PODの溶液(溶媒:
0.05Mリン酸緩衝液:pH6.5、0.1M Na
Cl、2mM EDTA)を得た。
Next, 0.3 ml of 0.1 M phosphate buffer (pH 7.0) was added to and dissolved in 3 mg of POD. To this
After adding 0.03 ml of a 00 mg / ml SMCC / dimethylformamide solution and reacting at room temperature for 1 hour, the reaction product was desalted and a maleimide group-introduced POD solution (solvent:
0.05M phosphate buffer: pH 6.5, 0.1M Na
Cl, 2 mM EDTA) was obtained.

【0033】これらのFab'化抗TSH抗体とマレイミ
ド基導入PODを0.1Mリン酸緩衝液(pH7.5)
中で直ちに混合し、4℃で16時間反応させた後、ゲル
濾過カラムクロマトグラフィーで分離精製を行い、PO
D標識Fab'化抗TSH抗体を調製した。
These Fab′-modified anti-TSH antibody and maleimide group-introduced POD were added to 0.1M phosphate buffer (pH 7.5).
Immediately mix in the solution, react at 4 ° C for 16 hours, and then perform separation and purification by gel filtration column chromatography,
A D-labeled Fab'-modified anti-TSH antibody was prepared.

【0034】比較例3 (SPDPを用いたPOD標識抗体の調製)架橋剤をN
−スクシンイミジル−3−(2’−ピリジルジチオ)プ
ロピオレート(SPDPと略記する)とした場合の例と
して、POD標識Fab'化マウス抗TSHモノクローナ
ル抗体を調製した。
Comparative Example 3 (Preparation of POD labeled antibody using SPDP)
As an example in which -succinimidyl-3- (2'-pyridyldithio) propiolate (abbreviated as SPDP) was used, a POD-labeled Fab'-conjugated mouse anti-TSH monoclonal antibody was prepared.

【0035】即ち、まず、実施例1と同様にFab'化抗
TSH抗体溶液を調製した。
That is, first, a Fab'-ized anti-TSH antibody solution was prepared in the same manner as in Example 1.

【0036】次に、POD3mgに0.1Mリン酸緩衝
液(pH7.0)を0.3ml加え溶解した。これに5
0mg/ml SPDP・ジメチルホルムアミド溶液を
0.03ml添加し、室温で1時間反応させた後、反応
物を脱塩処理してピリジルジスルフィド基導入POD溶
液(溶媒:0.05Mリン酸緩衝液:pH6.5、0.
1M NaCl、2mM EDTA)を得た。
Next, 0.3 ml of 0.1 M phosphate buffer (pH 7.0) was added to and dissolved in 3 mg of POD. 5 to this
After adding 0.03 ml of 0 mg / ml SPDP / dimethylformamide solution and reacting at room temperature for 1 hour, the reaction product was desalted and pyridyl disulfide group-introduced POD solution (solvent: 0.05 M phosphate buffer: pH 6) was added. .5, 0.
1M NaCl, 2mM EDTA) was obtained.

【0037】これらのFab'化抗TSH抗体とピリジル
ジスルフィド基導入PODを0.1Mリン酸緩衝液(p
H7.0)中で直ちに混合し、4℃で16時間反応させ
た後、ゲル濾過カラムクロマトグラフィーで分離精製を
行い、POD標識Fab'化抗TSH抗体を調製した。
These Fab′-modified anti-TSH antibody and PY with pyridyl disulfide group were added to 0.1M phosphate buffer (p
The mixture was immediately mixed in H7.0), reacted at 4 ° C. for 16 hours, and then separated and purified by gel filtration column chromatography to prepare a POD-labeled Fab′-conjugated anti-TSH antibody.

【0038】試験例1 (POD標識Fab'化抗TSH抗体及びPOD標識抗T
SH抗体の酵素活性及び反応性の測定)実施例1、比較
例1〜3で得られた酵素標識抗体の安定性を調べるため
に、抗体溶液を一定期間室温にて保存した後、下記の方
法により酵素活性の変化及び抗体の抗原との反応性の変
化を測定した。 (1)酵素活性の経時変化 酵素活性の測定は以下の測定法で行った。反応容器とし
て用意したプラスチックチューブに、西洋ワサビPOD
標識抗TSH抗体溶液(40ng/ml)を10μl加
え、37℃で5分間インキュベーションした。その後、
TMBZ・過酸化水素水溶液500μlを加え、さらに
37℃で2分間及び5分間インキュベーション後、1N
硫酸1mlにて反応を停止し、450nmにおける吸光
度を測定し、次式Iにより本品1μg当たりの酵素活性
を測定した。
Test Example 1 (POD-labeled Fab′-conjugated anti-TSH antibody and POD-labeled anti-T
Measurement of Enzyme Activity and Reactivity of SH Antibody) In order to examine the stability of the enzyme-labeled antibodies obtained in Example 1 and Comparative Examples 1 to 3, the antibody solution was stored at room temperature for a certain period of time, and then the following method was used. Was used to measure changes in enzyme activity and changes in antibody reactivity with antigen. (1) Time-dependent change of enzyme activity The enzyme activity was measured by the following measuring method. Put the horseradish POD in the plastic tube prepared as a reaction container.
10 μl of a labeled anti-TSH antibody solution (40 ng / ml) was added, and the mixture was incubated at 37 ° C. for 5 minutes. afterwards,
After adding 500 μl of TMBZ / hydrogen peroxide solution and further incubating at 37 ° C. for 2 minutes and 5 minutes, 1N
The reaction was stopped with 1 ml of sulfuric acid, the absorbance at 450 nm was measured, and the enzyme activity per 1 μg of the product was measured by the following formula I.

【0039】[0039]

【数1】 酵素活性の経時変化(経時安定性)は、保存前及び保存
後の酵素標識抗体を用いて上記の方法で測定した吸光度
について、保存後のものの吸光度を、保存前のものの吸
光度を100とした時の相対値として表すことで評価し
た。得られた結果を表1に示す。
[Equation 1] The change with time (stability over time) of the enzyme activity is the absorbance measured by the above method using the enzyme-labeled antibody before and after storage, when the absorbance after storage is taken as the absorbance before storage is 100. It evaluated by expressing as a relative value of. The results obtained are shown in Table 1.

【0040】[0040]

【表1】 表1に示されたとおり、本発明の酵素標識抗体(実施例
1)の標識酵素の活性値の低下率は極めて低く、標識酵
素の活性は安定に保持されることが判明した。また、ス
ルホン化SIABを用いた従来の酵素標識抗体調製法で
得られた酵素標識抗体(比較例1)、或いはSIAB以
外の架橋剤を用いた調製法で得られた酵素標識抗体(比
較例2、3)においても実施例1とほぼ同様の結果が得
られた。 (2)抗体の反応性の経時変化 抗体の抗原との反応性については、酵素免疫測定法の原
理を用いて以下の通り行った。反応容器としてのプラス
チックチューブに抗TSH抗体固定化磁性微粒子懸濁液
(1.0mg/ml)50μlと標準溶液(TSH濃
度:40μIU/ml)80μlを加え、37℃で5分
間インキュベーションした。続いて西洋ワサビPOD標
識抗TSH抗体50μlを加え、37℃で5分間インキ
ュベーションした。その後、磁石により磁性微粒子を集
積させた後、洗浄液にて洗浄操作を3回行い、TMBZ
・過酸化水素水溶液300μlを加え、さらに37℃で
5分間インキュベーション後、1N硫酸1mlにて反応
を停止し、450nmにおける吸光度を測定した。
[Table 1] As shown in Table 1, it was found that the decrease rate of the activity value of the labeling enzyme of the enzyme-labeled antibody of the present invention (Example 1) was extremely low, and the activity of the labeling enzyme was stably maintained. In addition, an enzyme-labeled antibody obtained by a conventional enzyme-labeled antibody preparation method using sulfonated SIAB (Comparative Example 1) or an enzyme-labeled antibody obtained by a preparation method using a crosslinking agent other than SIAB (Comparative Example 2) Also in 3), almost the same results as in Example 1 were obtained. (2) Time-dependent change in antibody reactivity The reactivity of the antibody with the antigen was measured as follows using the principle of enzyme immunoassay. To a plastic tube as a reaction container, 50 μl of a suspension of magnetic fine particles having an anti-TSH antibody (1.0 mg / ml) and 80 μl of a standard solution (TSH concentration: 40 μIU / ml) were added, and the mixture was incubated at 37 ° C. for 5 minutes. Subsequently, 50 μl of horseradish POD-labeled anti-TSH antibody was added and incubated at 37 ° C. for 5 minutes. After that, the magnetic fine particles are accumulated by the magnet, and then the washing operation is performed three times with the washing liquid to remove TMBZ.
-300 μl of hydrogen peroxide solution was added, and after further incubation at 37 ° C. for 5 minutes, the reaction was stopped with 1 ml of 1N sulfuric acid, and the absorbance at 450 nm was measured.

【0041】抗体反応性の経時変化(経時安定性)は、
保存前及び保存後の酵素標識抗体を用いて上記の方法で
測定した吸光度について、保存後のものの吸光度を、保
存前のものの吸光度を100とした時の相対値として表
すことで評価した。得られた結果を表2に示す。
The change in antibody reactivity over time (stability over time) is
The absorbance measured by the above method using the enzyme-labeled antibody before and after storage was evaluated by expressing the absorbance after storage as a relative value when the absorbance before storage was 100. The obtained results are shown in Table 2.

【0042】[0042]

【表2】 その結果、本発明の酵素標識抗体(実施例1)の抗体反
応性の経時的な減少幅は、先の表1に示された標識酵素
の活性値の減少幅とほぼ同じであり、抗体の抗原との反
応性は安定に維持されていることがわかる。すなわち、
本発明の酵素標識抗体は経時安定性に優れるものであっ
た。
[Table 2] As a result, the degree of decrease in the antibody reactivity of the enzyme-labeled antibody of the present invention (Example 1) over time is almost the same as the degree of decrease in the activity value of the labeling enzyme shown in Table 1 above, It can be seen that the reactivity with the antigen is stably maintained. That is,
The enzyme-labeled antibody of the present invention was excellent in stability over time.

【0043】一方、SIABを用いた従来の酵素標識抗
体調製法で得られた抗体(比較例1)、或いはSIAB
以外の架橋剤を用いた調製法で得られた抗体(比較例
2、3)においては、先の表1に示すように標識酵素の
活性自体は安定であるにも拘らず、吸光度の減少率は実
施例1よりも大きく。これらの比較例で得た酵素標識抗
体の経時安定性が不十分であった。
On the other hand, an antibody obtained by a conventional enzyme-labeled antibody preparation method using SIAB (Comparative Example 1), or SIAB
In the antibodies (Comparative Examples 2 and 3) obtained by the preparation method using a cross-linking agent other than the above, as shown in Table 1 above, the activity of the labeling enzyme itself was stable, but the decrease rate of absorbance was Is larger than in Example 1. The enzyme-labeled antibodies obtained in these Comparative Examples had insufficient stability over time.

【0044】実施例2 (TSH免疫学的測定用キット)TSH標準液を調製し
た。その他、測定に必要な試薬を調製し、表3に示すT
SH免疫学的測定用キットを構成した。次に、本キット
を用いたTSHの測定を以下のようにして行った。
Example 2 (TSH immunological measurement kit) A TSH standard solution was prepared. In addition, the reagents necessary for the measurement were prepared, and T shown in Table 3 was used.
An SH immunological assay kit was constructed. Next, TSH measurement using this kit was performed as follows.

【0045】即ち、プラスチックチューブに抗TSH抗
体結合磁性微粒子懸濁液50μlとTSH標準溶液或い
は検体80μlを加え、37℃で5分間インキュベーシ
ョンした。西洋ワサビPOD標識抗TSH抗体溶液50
μlを加え、37℃で5分間インキュベーションした。
その後、磁石により磁性微粒子を集積させた後、洗浄液
にて洗浄操作を3回行った。洗浄の終わった試料に発色
液38mlと酵素基質液200μlの混合液300μl
を加え、更に37℃で5分間インキュベーションした。
その後、反応停止液(1N硫酸溶液)1mlを添加して
反応を停止し、得られた反応液の450nmにおける吸
光度を測定した。図1にTSH測定用標準溶液の検量線
を示した。
That is, 50 μl of anti-TSH antibody-bound magnetic fine particle suspension and 80 μl of TSH standard solution or specimen were added to a plastic tube and incubated at 37 ° C. for 5 minutes. Horseradish POD-labeled anti-TSH antibody solution 50
μl was added and incubated at 37 ° C. for 5 minutes.
Then, after the magnetic fine particles were collected by the magnet, the washing operation was performed three times with the washing liquid. To the washed sample, 300 μl of mixed solution of 38 ml of coloring solution and 200 μl of enzyme substrate solution
Was added and the mixture was further incubated at 37 ° C. for 5 minutes.
Then, 1 ml of a reaction stop solution (1N sulfuric acid solution) was added to stop the reaction, and the absorbance of the obtained reaction solution at 450 nm was measured. The calibration curve of the standard solution for TSH measurement is shown in FIG.

【0046】[0046]

【表3】 実施例3 (スルホン化SIABを用いたPOD標識Fab'化ウサ
ギ抗β2ミクログロブリンポリクローナル抗体の調製)
ウサギ抗β2ミクログロブリンポリクローナル抗体(以
下抗β2MG抗体と略す)3mgを0.1Mクエン酸緩
衝液(pH4.5) 1mlに加えて溶解した。これに
1%ペプシン溶液を0.35ml添加し、37℃で16
時間反応させた。反応物をゲル濾過カラムクロマトグラ
フィー(TSKgel G3000SW)で分離精製
し、F(ab')2画分を回収した。得られたF(ab')2画分に
最終濃度が0.01Mとなるように2−メルカプトエチ
ルアミンを添加した後、37℃で1.5時間反応させ
た。反応後、反応物を脱塩処理して抗β2MG抗体Fab'
フラグメントの溶液(溶媒:0.05Mリン酸緩衝液:
pH6.5、0.1M NaCl、2mM EDTA)
を得た。
[Table 3] Example 3 (Preparation of POD-labeled Fab'-labeled rabbit anti-β 2 microglobulin polyclonal antibody using sulfonated SIAB)
3 mg of rabbit anti-β 2 microglobulin polyclonal antibody (hereinafter abbreviated as anti-β 2 MG antibody) was added to 1 ml of 0.1 M citrate buffer (pH 4.5) and dissolved. 0.35 ml of a 1% pepsin solution was added to this, and the mixture was mixed at 37 ° C
Reacted for hours. The reaction product was separated and purified by gel filtration column chromatography (TSKgel G3000SW), and the F (ab ′) 2 fraction was collected. 2-Mercaptoethylamine was added to the obtained F (ab ') 2 fraction so that the final concentration was 0.01 M, and the mixture was reacted at 37 ° C for 1.5 hours. After the reaction, the reaction product is desalted to obtain anti-β 2 MG antibody Fab ′.
Fragment solution (solvent: 0.05M phosphate buffer:
(pH 6.5, 0.1 M NaCl, 2 mM EDTA)
Got

【0047】次に、POD3mgに0.1Mリン酸緩衝
液(pH7.0)を0.3ml加え溶解した。これに2
mg/mlの濃度のスルホン化SIAB溶液を0.3m
l添加した後、室温で1時間反応させた。反応後、反応
物を脱塩処理して4−ヨードアセチル−アミノベンゾエ
ート・POD複合体の溶液(溶媒:0.05Mリン酸緩
衝液:pH6.5、0.1M NaCl、2mM ED
TA)を得た。
Next, 0.3 ml of 0.1 M phosphate buffer (pH 7.0) was added to and dissolved in 3 mg of POD. 2 to this
0.3m of sulfonated SIAB solution with concentration of mg / ml
After the addition of 1, the reaction was carried out at room temperature for 1 hour. After the reaction, the reaction product is desalted to obtain a solution of 4-iodoacetyl-aminobenzoate / POD complex (solvent: 0.05M phosphate buffer: pH 6.5, 0.1M NaCl, 2mM ED).
TA) was obtained.

【0048】この4−ヨードアセチル−アミノベンゾエ
ート・POD複合体に、先の操作で得た抗β2MG抗体
Fab'フラグメントを0.1Mリン酸緩衝液(pH7.
0)中で直ちに混合し、4℃で16時間反応させた。反
応後、ゲル濾過カラムクロマトグラフィー(TSKge
l G3000SW)で分離精製を行い、POD標識Fa
b'化抗β2MG抗体を調製した。
To this 4-iodoacetyl-aminobenzoate / POD complex, the anti-β 2 MG antibody Fab ′ fragment obtained by the above operation was added in 0.1M phosphate buffer (pH 7.
The mixture was immediately mixed in 0) and reacted at 4 ° C. for 16 hours. After the reaction, gel filtration column chromatography (TSKge
Separation and purification with G3000SW, and POD-labeled Fa
A b′-modified anti-β 2 MG antibody was prepared.

【0049】比較例4 (スルホン化SIABを用いたPOD標識ウサギ抗β2
ミクログロブリンポリクローナル抗体の調製)比較のた
めに、SIABを用いた酵素標識抗体の調製の従来法の
例として、抗体とスルホン化SIABとを、抗体のアミ
ノ基を利用して結合し、また、スルホン化SIABとP
ODを、PODのメルカプト基を利用して結合すること
により酵素標識抗体を調製した。
Comparative Example 4 (POD-labeled rabbit anti-β 2 using sulfonated SIAB
Preparation of Microglobulin Polyclonal Antibody) For comparison, as an example of a conventional method for preparing an enzyme-labeled antibody using SIAB, an antibody and a sulfonated SIAB are bound using an amino group of the antibody, and SIB and P
An enzyme-labeled antibody was prepared by binding OD using the mercapto group of POD.

【0050】即ち、抗β2MG抗体3mgを0.1Mリ
ン酸緩衝液(pH7.0) 0.3mlに加え溶解し
た。これに2mg/mlの濃度のスルホン化SIAB溶
液を0.3ml添加し、室温で1時間反応させた後、反
応物を脱塩処理して4−ヨードアセチル−アミノベンゾ
エート・抗β2MG抗体複合体の溶液(溶媒:0.05
Mリン酸緩衝液:pH6.5、0.1M NaCl、2
mM EDTA)を得た。
That is, 3 mg of anti-β 2 MG antibody was added to 0.3 ml of 0.1M phosphate buffer (pH 7.0) and dissolved. 0.3 ml of a sulfonated SIAB solution having a concentration of 2 mg / ml was added thereto, and the mixture was reacted at room temperature for 1 hour, and then the reaction product was desalted and treated with 4-iodoacetyl-aminobenzoate / anti-β 2 MG antibody complex. Body solution (solvent: 0.05
M phosphate buffer: pH 6.5, 0.1 M NaCl, 2
(mM EDTA) was obtained.

【0051】この溶液と、比較例2と同様にして得たS
H化PODとを0.1Mリン酸緩衝液(pH7.5)中
で直ちに混合し、4℃で16時間反応させた後、ゲル濾
過カラムクロマトグラフィーで分離精製を行い、POD
標識抗β2MG抗体を調製した。
This solution and S obtained in the same manner as in Comparative Example 2 were used.
H-POD was immediately mixed with 0.1 M phosphate buffer (pH 7.5), reacted at 4 ° C. for 16 hours, and then separated and purified by gel filtration column chromatography to obtain POD.
A labeled anti-β 2 MG antibody was prepared.

【0052】比較例5 (SMCCを用いたPOD標識抗体の調製)架橋剤をS
MCCとした場合の例として、POD標識Fab'化ウサ
ギ抗β2ミクログロブリンポリクローナル抗体を調製し
た。
Comparative Example 5 (Preparation of POD labeled antibody using SMCC)
As an example of the case of using MCC, a POD-labeled Fab′-labeled rabbit anti-β 2 microglobulin polyclonal antibody was prepared.

【0053】即ち、まず実施例3と同様にFab'化抗β2
MG抗体溶液を調製し、更に比較例2と同様にマレイミ
ド基導入POD溶液を調製した。
That is, first, as in Example 3, Fab′-modified anti-β 2
An MG antibody solution was prepared, and a maleimide group-introduced POD solution was prepared in the same manner as in Comparative Example 2.

【0054】これらのFab'化抗β2MG抗体とマレイミ
ド基導入PODを0.1Mリン酸緩衝液(pH7.5)
中で直ちに混合し、4℃で16時間反応させた後、ゲル
濾過カラムクロマトグラフィーで分離精製を行い、PO
D標識Fab'化抗β2MG抗体を調製した。
The Fab′-modified anti-β 2 MG antibody and maleimide group-introduced POD were added to 0.1M phosphate buffer (pH 7.5).
Immediately mix in the solution, react at 4 ° C for 16 hours, and then perform separation and purification by gel filtration column chromatography,
A D-labeled Fab'-modified anti-β 2 MG antibody was prepared.

【0055】比較例6 (SPDPを用いたPOD標識抗体の調製)架橋剤をS
PDPとした場合の例として、POD標識Fab'化ウサ
ギ抗β2ミクログロブリンポリクローナル抗体を調製し
た。
Comparative Example 6 (Preparation of POD-labeled antibody using SPDP)
As an example of the case of using PDP, POD-labeled Fab′-labeled rabbit anti-β 2 microglobulin polyclonal antibody was prepared.

【0056】即ち、まず実施例3と同様にFab'化抗β2
MG抗体溶液を調製し、更に比較例3と同様にピリジル
ジスルフィド基導入POD溶液を得た。
That is, first, as in Example 3, Fab′-ized anti-β 2
An MG antibody solution was prepared, and a pyridyl disulfide group-introduced POD solution was obtained in the same manner as in Comparative Example 3.

【0057】これらのFab'化抗β2MG抗体とピリジル
ジスルフィド基導入PODとを0.1Mリン酸緩衝液
(pH7.5)中で直ちに混合し、4℃で16時間反応
させた後、ゲル濾過カラムクロマトグラフィーで分離精
製を行い、POD標識Fab'化抗β2MG抗体を調製し
た。
These Fab′-modified anti-β 2 MG antibodies and pyridyl disulfide group-introduced POD were immediately mixed in 0.1M phosphate buffer (pH 7.5), reacted at 4 ° C. for 16 hours, and then gelled. Separation and purification were carried out by filtration column chromatography to prepare a POD-labeled Fab′-conjugated anti-β 2 MG antibody.

【0058】試験例2 (POD標識Fab'化抗TSH抗体及びPOD標識抗T
SH抗体の酵素活性及び反応性の測定)実施例3、比較
例4〜6で得られたPOD標識(Fab'化)抗β2MG抗
体の安定性を調べるために、抗体溶液を一定期間室温に
て保存した後、下記の方法により酵素活性の変化及び抗
体の抗原との反応性の変化を測定した。 (1)酵素活性の経時変化 酵素活性の測定は試験例1と同様の操作で行った。但
し、西洋ワサビPOD標識抗TSH抗体溶液の代わりに
西洋ワサビPOD標識抗β2MG抗体溶液を用いた。保
存前及び保存後の抗体を用いた場合の吸光度を測定し、
結果を保存前抗体を用いた場合の吸光度を100とした
時の相対値として表した(表4)。
Test Example 2 (POD-labeled Fab′-conjugated anti-TSH antibody and POD-labeled anti-T antibody
Measurement of Enzyme Activity and Reactivity of SH Antibody) To examine the stability of the POD-labeled (Fab′-modified) anti-β 2 MG antibody obtained in Example 3 and Comparative Examples 4 to 6, the antibody solution was kept at room temperature for a certain period of time. After storing in, the change in enzyme activity and the change in antibody reactivity with antigen were measured by the following methods. (1) Time-dependent change in enzyme activity The enzyme activity was measured in the same manner as in Test Example 1. However, a horseradish POD-labeled anti-β 2 MG antibody solution was used instead of the horseradish POD-labeled anti-TSH antibody solution. Measure the absorbance when using the antibody before and after storage,
The results were expressed as a relative value when the absorbance when the antibody before storage was used was 100 (Table 4).

【0059】その結果、本発明の酵素標識抗体の酵素活
性値は、SIABを用いた従来の酵素標識抗体調製法で
得られた抗体、或いはSIAB以外の架橋剤を用いた調
製法で得られた抗体の活性値とほぼ同様であった。
As a result, the enzyme activity value of the enzyme-labeled antibody of the present invention was obtained by the antibody obtained by the conventional enzyme-labeled antibody preparation method using SIAB or the preparation method using a crosslinking agent other than SIAB. It was almost the same as the antibody activity value.

【0060】[0060]

【表4】 (2)抗体の反応性の経時変化 免疫学的測定は酵素免疫測定法の原理を用いて以下の通
り行った。反応容器としてプラスチックチューブを用い
た。このチューブに抗β2MG抗体固定化磁性微粒子懸
濁液(1.0mg/ml)100μlと標準溶液(β2
ミクログロブリン濃度:2000ng/ml)5μlを
加え、37℃で5分間インキュベーションした。磁石に
より磁性微粒子を集積させた後、洗浄液にて洗浄を行っ
た。続いて西洋ワサビPOD標識抗β2MG抗体100
μlを加え、37℃で5分間インキュベーションした。
その後、上記要領にて洗浄操作を3回行い、TMBZ・
過酸化水素水溶液300μlを加え、さらに37℃で5
分間インキュベーション後、1N硫酸1mlにて反応を
停止し、450nmにおける吸光度を測定した。保存前
及び保存後の抗体を用いた場合の吸光度を測定し、結果
を保存前抗体を用いた場合の吸光度を100とした時の
相対値として表した(表5)。
[Table 4] (2) Changes in antibody reactivity over time Immunological measurements were performed as follows using the principle of enzyme immunoassay. A plastic tube was used as the reaction container. Into this tube, 100 μl of a suspension of anti-β 2 MG antibody-immobilized magnetic particles (1.0 mg / ml) and a standard solution (β 2
Microglobulin concentration: 2000 ng / ml) (5 μl) was added, and the mixture was incubated at 37 ° C. for 5 minutes. After the magnetic fine particles were accumulated with a magnet, cleaning was performed with a cleaning liquid. Then, horseradish POD-labeled anti-β 2 MG antibody 100
μl was added and incubated at 37 ° C. for 5 minutes.
After that, perform the washing operation 3 times as described above, and
Add 300 μl of hydrogen peroxide solution, and add 5 more at 37 ℃.
After incubation for 1 minute, the reaction was stopped with 1 ml of 1N sulfuric acid, and the absorbance at 450 nm was measured. Absorbances were measured using the antibody before and after storage, and the results were expressed as relative values when the absorbance when using the antibody before storage was 100 (Table 5).

【0061】その結果、本発明の酵素標識抗体の反応性
は、SIABを用いた従来の酵素標識抗体調製法で得ら
れた抗体、或いはSIAB以外の架橋剤を用いた調製法
で得られた抗体の反応性と比べて経時的減少が少なく、
本発明の酵素標識抗体は、経時安定性に優れていること
がわかった。
As a result, the reactivity of the enzyme-labeled antibody of the present invention was found to be the antibody obtained by the conventional enzyme-labeled antibody preparation method using SIAB, or the antibody obtained by the preparation method using a crosslinking agent other than SIAB. The decrease over time is less than that of
It was found that the enzyme-labeled antibody of the present invention has excellent stability over time.

【0062】[0062]

【表5】 実施例4 (β2MG免疫学的測定用キット)β2MG標準液を調製
した。その他測定に必要な試薬を調製し、表6に示すβ
2MG免疫学的測定用キットを構成した。本キットを用
いたβ2MGの測定は以下のようにして行う。
[Table 5] Example 4 (Kit for β 2 MG immunological measurement) A β 2 MG standard solution was prepared. Other reagents necessary for measurement were prepared and β shown in Table 6 was used.
2 MG immunological assay kit was constructed. Β 2 MG measurement using this kit is performed as follows.

【0063】即ち、プラスチックチューブに抗β2MG
抗体結合磁性微粒子懸濁液100μlとβ2MG標準溶
液或いは検体5μlを加え、37℃で5分間インキュベ
ーションする。磁石により磁性微粒子を集積させた後、
洗浄液により洗浄を行う。西洋ワサビPOD標識抗β2
MG抗体溶液100μlを加え、37℃で5分間インキ
ュベーションする。その後上記要領で3回洗浄を行う。
洗浄の終わった試料に発色液38mlと酵素基質液20
0μlの混合液300μlを加え、更に37℃で5分間
インキュベーションする。その後、反応停止液(1N硫
酸溶液)1mlを添加して反応を停止し、得られた反応
液の450nmにおける吸光度を測定する。図2にβ2
MG測定用標準溶液の検量線を示した。
That is, an anti-β 2 MG is added to a plastic tube.
100 μl of antibody-bound magnetic fine particle suspension and 5 μl of β 2 MG standard solution or specimen are added and incubated at 37 ° C. for 5 minutes. After accumulating magnetic fine particles with a magnet,
Wash with a washing solution. Horseradish POD-labeled anti-β 2
Add 100 μl of MG antibody solution and incubate at 37 ° C. for 5 minutes. After that, washing is performed three times in the same manner as described above.
38 ml of color-developing solution and 20 of enzyme substrate solution are added to the washed sample.
300 μl of 0 μl of the mixed solution is added, and the mixture is further incubated at 37 ° C. for 5 minutes. Then, 1 ml of a reaction stop solution (1N sulfuric acid solution) is added to stop the reaction, and the absorbance of the obtained reaction solution at 450 nm is measured. Β 2 in Figure 2
The calibration curve of the standard solution for MG measurement is shown.

【0064】[0064]

【表6】 [Table 6]

【0065】[0065]

【発明の効果】本発明の酵素標識抗体は優れた経時安定
性を有するため、該酵素標識抗体を用いると免疫学的測
定の結果について優れた再現性が得られる。
EFFECT OF THE INVENTION Since the enzyme-labeled antibody of the present invention has excellent stability over time, when the enzyme-labeled antibody is used, excellent reproducibility of the results of immunological measurement can be obtained.

【0066】また、本発明の酵素標識抗体を用いた免疫
学的測定用キットは長期間保存可能であるため大変経済
的である。
The immunological assay kit using the enzyme-labeled antibody of the present invention can be stored for a long period of time, which is very economical.

【図面の簡単な説明】[Brief description of drawings]

【図1】TSH測定用標準溶液の検量線を示す図であ
る。
FIG. 1 is a diagram showing a calibration curve of a standard solution for TSH measurement.

【図2】β2MG測定用標準溶液の検量線を示す図であ
る。
FIG. 2 is a diagram showing a calibration curve of a standard solution for β 2 MG measurement.

───────────────────────────────────────────────────── フロントページの続き (56)参考文献 特開 昭55−34087(JP,A) 特開 昭63−91563(JP,A) 特開 昭58−149700(JP,A) 特開 昭55−120558(JP,A) (58)調査した分野(Int.Cl.7,DB名) G01N 33/535 C12Q 1/28 G01N 33/566 ─────────────────────────────────────────────────── --- Continued from the front page (56) Reference JP-A-55-34087 (JP, A) JP-A-63-91563 (JP, A) JP-A-58-149700 (JP, A) JP-A-55- 120558 (JP, A) (58) Fields investigated (Int.Cl. 7 , DB name) G01N 33/535 C12Q 1/28 G01N 33/566

Claims (7)

(57)【特許請求の範囲】(57) [Claims] 【請求項1】 抗体に標識酵素を架橋剤を介して結合さ
せた酵素標識抗体において、下記式(1): 【化1】 [上記式(1)中、Abは抗体を、PODはペルオキシ
ダーゼを表わす。]で表わされる構造を有することを特
徴とする酵素標識抗体。
1. An enzyme-labeled antibody obtained by binding a labeling enzyme to an antibody via a cross-linking agent, wherein the following formula (1): [In the above formula (1), Ab represents an antibody and POD represents a peroxidase. ] The enzyme label | marker antibody characterized by having a structure represented by these.
【請求項2】 前記抗体がFab’フラグメントである請
求項1に記載の酵素標識抗体。
2. The enzyme-labeled antibody according to claim 1, wherein the antibody is a Fab ′ fragment.
【請求項3】 前記抗体が、予めメルカプト基が導入さ
れたものである請求項1または2に記載の酵素標識抗
体。
3. The enzyme-labeled antibody according to claim 1 or 2, wherein the antibody has a mercapto group introduced in advance.
【請求項4】 抗体に、N−スクシンイミジル−(4−
ヨードアセチル)−アミノベンゾエート又はスルホスク
シンイミジル−(4−ヨードアセチル)−アミノベンゾ
エートからなる架橋剤を用いて標識酵素を結合させるこ
とにより下記式(1): 【化2】 [上記式(1)中、Abは抗体を、PODはペルオキシ
ダーゼを表わす。]で表わされる構造を有する酵素標識
抗体を調製する方法において、 (a)前記抗体としてメルカプト基を有するものを用
い、該メルカプト基と、前記架橋剤のヨードアセチル基
とを反応させることでこれらを結合する過程と、 (b)前記標識酵素をそのアミノ基を利用して、前記架
橋剤のスクシンイミド基またはホスホスクシンイミド基
と置換することでこれらを結合する過程とを有すること
を特徴とする酵素標識抗体の調製方法。
4. The antibody is added to N-succinimidyl- (4-
By linking the labeling enzyme with a cross-linking agent consisting of iodoacetyl) -aminobenzoate or sulfosuccinimidyl- (4-iodoacetyl) -aminobenzoate, the following formula (1): [In the above formula (1), Ab represents an antibody and POD represents a peroxidase. ] In the method for preparing an enzyme-labeled antibody having a structure represented by: (a) using an antibody having a mercapto group as the antibody, and reacting the mercapto group with the iodoacetyl group of the crosslinking agent An enzyme label comprising a step of binding, and (b) a step of binding the labeling enzyme by substituting the labeling enzyme with a succinimide group or a phosphosuccinimide group of the cross-linking agent by utilizing its amino group. Method for preparing antibody.
【請求項5】 前記抗体がFab'フラグメントである請
求項4に記載の酵素標識抗体の調製方法。
5. The method for preparing an enzyme-labeled antibody according to claim 4, wherein the antibody is a Fab ′ fragment.
【請求項6】 前記抗体が、予めメルカプト基が導入さ
れたものである請求項4または5に記載の酵素標識抗体
の調製方法。
6. The method for preparing an enzyme-labeled antibody according to claim 4 or 5, wherein the antibody has a mercapto group introduced in advance.
【請求項7】 試料と、請求項1〜3のいずれかに記載
の酵素標識抗体を反応させる過程と、該試料中に抗原が
含まれる場合に形成される抗原−酵素標識抗体コンプレ
ックスを、該抗体に結合させた標識酵素を利用して検出
する過程とを有することを特徴とする免疫学的測定方
法。
7. A process of reacting a sample with the enzyme-labeled antibody according to any one of claims 1 to 3, and an antigen-enzyme-labeled antibody complex formed when the sample contains an antigen, And a step of detecting using a labeling enzyme bound to an antibody.
JP16535595A 1995-06-30 1995-06-30 Stabilized enzyme-labeled antibody Expired - Lifetime JP3516526B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP16535595A JP3516526B2 (en) 1995-06-30 1995-06-30 Stabilized enzyme-labeled antibody

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16535595A JP3516526B2 (en) 1995-06-30 1995-06-30 Stabilized enzyme-labeled antibody

Publications (2)

Publication Number Publication Date
JPH0915241A JPH0915241A (en) 1997-01-17
JP3516526B2 true JP3516526B2 (en) 2004-04-05

Family

ID=15810798

Family Applications (1)

Application Number Title Priority Date Filing Date
JP16535595A Expired - Lifetime JP3516526B2 (en) 1995-06-30 1995-06-30 Stabilized enzyme-labeled antibody

Country Status (1)

Country Link
JP (1) JP3516526B2 (en)

Also Published As

Publication number Publication date
JPH0915241A (en) 1997-01-17

Similar Documents

Publication Publication Date Title
US6184042B1 (en) Method for reducing hook effect in an immunoassay
JP2726793B2 (en) Immunoassay
AU612907B2 (en) Process and reagent for the determination of a specifically bindable substance
US5332679A (en) Method for specific binding assays using a releasable ligand
US5654159A (en) Assay with signal detection in the presence of a suspended solid support
JPH0756487B2 (en) Immunoassay for detecting ligands
JPH07260784A (en) Quaternary ammonium immunogen conjugate and immunoassay reagent
US20100248218A1 (en) Conjugates, and use thereof in detection methods
JPWO2019194280A1 (en) Immunoassay method for hepatitis B virus antigen
US5792606A (en) Nucleic acid hybridization based assay for determining a substance of interest
JPH07507388A (en) Methods for determining the amount of ligand in biological fluids and kits for carrying out such methods
US8628933B2 (en) Homogeneous detection method
Gómez-Sánchez et al. Biotin-hydrazide derivatives for the development of steroid enzyme-linked immunoassays
JP2004538447A (en) Kinetic assay
US5437981A (en) Method for the immunological determination of ligands
JP3516526B2 (en) Stabilized enzyme-labeled antibody
JP3847983B2 (en) Reagent for immunological analysis, immunological analysis method, and kit for immunological analysis
Basu et al. The influence of spacer-containing enzyme conjugate on the sensitivity and specificity of enzyme immunoassays for hapten
HU228077B1 (en) Cobalamin assay
US5278081A (en) Method for the determination of an immunologically bindable substance
JPH03170058A (en) Reagent complex for immunoassay
EP0404783A1 (en) Immunoassays using monoclonal antibodies directed against natural binding proteins
CA2547353A1 (en) Conjugates, and use thereof in detection methods
JPH0346565A (en) Enzyme immunoassay utilizing magnetic material
JP2000074917A (en) Measuring method for diacetyl polyamine and kit therefor

Legal Events

Date Code Title Description
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20040107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20040120

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20080130

Year of fee payment: 4

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090130

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20090130

Year of fee payment: 5

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100130

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20100130

Year of fee payment: 6

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110130

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20110130

Year of fee payment: 7

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20120130

Year of fee payment: 8

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130130

Year of fee payment: 9

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140130

Year of fee payment: 10

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term